PSK Pharma has registered the drug Saxagliptin PSK (saxagliptin), a generic of AstraZeneca’s Onglyza, for the treatment of type 2 diabetes.
Saxagliptin PSK, available as 2.5 mg and 5 mg tablets, is indicated for adults over 18 years of age for the treatment of type 2 diabetes as an adjunct to diet and exercise to improve glycemic control.
“According to public data, over 200,000 packs of saxagliptin were sold in the budget-funded segment last year. At our production facility in the Dubna Special Economic Zone, we can produce up to 1.9 million packs per year, which allows us to meet market demand even with potential growth in the coming years,” noted the company’s General Director, Evgenia Shapiro.
According to the State Register of Medicinal Products (GRLS), four generic versions of saxagliptin are now present on the Russian market. In addition to PSK Pharma, generic drugs are produced by R-Pharm (Dixaptin), Velfarm-M (Saglivel), and Atoll (Saxagliptin).
PSK Pharma reminded that saxagliptin can be used both as monotherapy and as part of combination therapy, for example, with metformin.